



CLINICAL GUIDELINE

Acute Severe Colitis Management, Glasgow Royal Infirmary

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	6
Does this version include changes to clinical advice:	No
Date Approved:	17 th July 2025
Date of Next Review:	31 st July 2028
Lead Author:	Daniel Gaya
Approval Group:	North Sector Emergency Department Clinical Governance Group

Important Note:

The online version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

GRI protocol for management of acute severe colitis (V33 May 201)

Truelove & Witt's criteria define these patients

(n.b. differentials include UC, CD, infection, ischaemia, diverticulitis)

- Bowels open >6 per 24 hrs + any one of
 - Hb<10.5
 - Pyrexia
 - Pulse >90
 - ESR>30

Investigations

- History & examination
 - 4 hrly obs
 - Stool chart
 - Stool C&S/C diff toxin x 3 (on admission)
 - K⁺, CRP & albumin (daily)
 - AXR (on day one and daily thereafter if colonic dilatation noted)
 - Urgent unprepared sigmoidoscopy & urgent biopsies (ideally <24 hrs of admission,)
- Referral to consultant gastroenterologist and to consultant colorectal surgeon & stoma care sister (at the earliest convenience)

Management

- NBM & IVI
- Avoid antidiarrhoeals, NSAIDs & opiates
- LMWH prophylaxis
- IV antibiotics (if known Crohn's colitis, pyrexial or colonic dilatation on AXR)
- IV corticosteroid : **Methylprednisolone 30mg twice daily**

Day 3 post admission - risk stratification

1. Travis criteria

SF>8/24hrs or SF>3 and CRP>45

(85% of these patient will require a colectomy)

2. Ho score (see table opposite)

score of 0-9 predicts the risk of failing medical therapy; low (score 0-1, 11% risk), intermediate (score 2-3, 45% risk) & high (score ≥4, 85% risk)

Table 4. Integer risk score attributable to each category derived from the coefficients of the logistic regression equation

Variables	Score
Mean stool frequency	
< 4	0
4 ≤ 6	1
6 ≤ 9	2
> 9	4
Colonic dilatation	4
Hypoalbuminaemia	
< 30 g/L	1

Overall risk core = [score attributable to mean stool frequency (0, 1, 2 or 4)] + [presence of colonic dilatation (0 or 4)] + [presence of hypoalbuminaemia (0 or 1)]. Minimum score = 0, maximum score = 9.

HIGH RISK: Travis criteria met, Ho score ≥ 4 &/or 'broken through' azathioprine/equivalent immunosuppression



discussion with consultant colorectal surgeon/gastroenterologist & stoma sister re urgent colectomy

INTERMEDIATE RISK: Ho score intermediate risk (2-3)



discussion with patient regarding colectomy versus 2nd line medical therapy. If, after appropriate counselling, patient not willing to consider surgery, then decisions regarding potential 2nd line therapy should be taken only after discussion with the consultant gastroenterologist.

If responding to medical Rx, then start oral & topical 5ASA. The switch from IV to oral steroid will be decided by the managing consultant.